Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This research aims to:
A. Understand and analyze the current status of breast cancer diagnosis and treatment; B. Publish an annual report on diagnosis and treatment; C. Data sharing, dynamic evaluation; D. Evaluate consensus and guideline promotion and implementation effects; E. Propose and set clinical quality standards for industry associations, and propose improvement goals; F. Provide a basis for industry associations to formulate specialized training programs; G. To provide assistance in the formulation of health insurance policies; H. Provide a platform for clinical research on breast cancer; I. Provide evidence for the formulation of clinical guidelines and consensus
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The study did not involve intervention in the patient's treatment regimen | Procedure | This study is based on a prospective database platform to register the occurrence, treatment and prognosis of breast cancer in China, so there is no clear exposure factor. This study was a prospective cohort study, which did not intervene in exposure factors, but only assessed the occurrence, treatment, and prognosis of breast cancer in China. |
| Measure | Description | Time Frame |
|---|---|---|
| The current status of patients diagnosed with breast cancer and their types of treatment | Including but not limited to the patient receiving different surgical methods, different drugs, neoadjuvant and adjuvant therapy, etc. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months |
| Prognostic outcomes of patients | Including patient disease-free survival and overall survival. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months |
| Measure | Description | Time Frame |
|---|---|---|
| Prognosis-recurrence-free survival | The time from the diagnosis of breast cancer to the recurrence or metastasis of the patient, and the parts involved. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with malignant breast tumors
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jiong Wu, M.D | Contact | +862164175590 | 88607 | wujiong1122@vip.sina.com |
| Name | Affiliation | Role |
|---|---|---|
| Jiong Wu, M.D | Cancer Hospital/ Institute, Fudan University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cancer Hospital/ Institute, Fudan University | Recruiting | Shanghai | Shanghai Municipality | 200032 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Prognosis-overall survival |
As the time from diagnosis of breast cancer to death of the patient |
| From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months |
| D017437 |
| Skin and Connective Tissue Diseases |